Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Acurx Pharmaceuticals, Inc. (ACXP)

Acurx to effect 1-for-20 reverse stock split effective August 4, 2025

Neutral Impact 3 of 5 shareholder Written later

Acurx Pharmaceuticals filed a certificate of amendment to combine every twenty shares of its common stock into one share, effective 4:01 p.m. Eastern Time on August 4, 2025. The company says the split is intended to raise the per-share trading price so it can regain compliance with Nasdaq's minimum bid price requirement. Shareholders will receive cash in lieu of any fractional shares, and the number of authorized shares will not change.

Key points

  • Ratio is 1-for-20, with shares expected to trade on a split-adjusted basis on The Nasdaq Capital Market from August 5, 2025 under the symbol ACXP
  • Shares outstanding are expected to fall from about 30,764,540 as of July 24, 2025 to about 1,538,227 after the split
  • Stockholders approved the reverse split at the annual meeting held July 17, 2025
  • The stated purpose is to help the company regain compliance with Nasdaq's minimum bid price requirement

The filing

CompanyAcurx Pharmaceuticals, Inc. (ACXP)
Form8-K, current report
Filed with the SECJul 31, 2025, 9:29 AM ET
Accession number0001104659-25-072529

Items reported: 3.03 Change to Shareholder Rights5.03 Bylaw / Charter Amendment8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 31, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.